Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

Hengrui Pharma and Kailera Therapeutics announced positive late-stage trial data for their experimental weekly obesity injection, HRS9531, in China, showing nearly 18% average body weight loss over 48 weeks and positioning it as a significant potential competitor to Eli Lilly's Zepbound in the booming weight loss market. Separately, 23andMe co-founder Anne Wojcicki, via her nonprofit TTAM Research Institute, successfully acquired the embattled genetic testing company for $305 million in a bankruptcy auction, regaining control and ensuring the continuation of its core operations.

Analysis

Positive late-stage trial data from Hengrui Pharma and Kailera Therapeutics for their obesity drug, HRS9531, introduces a credible future competitor into the high-growth weight-loss market. The drug achieved nearly 18% average body weight loss at 48 weeks in a China-based trial, demonstrating strong efficacy that approaches the performance of Eli Lilly's market-leading Zepbound, which showed up to 21% loss over a longer 72-week period. As a dual GLP-1/GIP agonist, HRS9531 directly mimics Zepbound's mechanism, positioning it as a more significant long-term threat to Eli Lilly than to Novo Nordisk's single-agonist Wegovy. While the trial's smaller size of 500 patients and the lack of detailed safety data warrant caution, the absence of a weight-loss plateau at 48 weeks is a promising signal. The licensing deal, valued at over $100 million in upfront payments and nearly $6 billion in potential milestones for ex-China rights, underscores the asset's perceived value, though a U.S. market entry remains several years away pending global studies. Separately, the acquisition of 23andMe's assets for $305 million by co-founder Anne Wojcicki's nonprofit, TTAM, concludes the public company's financial distress and Chapter 11 bankruptcy. This move, which successfully outbid Regeneron's $256 million offer, ensures the continuity of 23andMe’s genetic testing services but highlights the failure of its previous business model as a public entity, a sentiment reflected in its deeply negative ticker score (-0.7).

Key Decisions for Investors

• Investors in Eli Lilly and Novo Nordisk should view the HRS9531 data as a validation of the dual-agonist approach but must monitor Kailera's future global trials as a legitimate, albeit distant, competitive threat to long-term market share.
• The successful acquisition of 23andMe out of bankruptcy means any remaining value in the public stock (ME) is effectively eliminated, and the focus now shifts entirely to the operational viability of the ongoing business under a new private, nonprofit structure.
• Regeneron's failed bid for 23andMe's assets signals its strategic intent to acquire genetic data to fuel its R&D; investors should anticipate that the company may pursue similar bolt-on acquisitions in the genomics space.
• The high-value licensing deal for HRS9531's ex-China rights highlights significant investor appetite for promising obesity assets, suggesting potential upside for private or public companies with credible candidates in their pipelines, even at early stages.